Immunity Royalty Holdings

Immunity Royalty Holdings is a specialized financing subsidiary of ImmunityBio, a clinical-stage immunotherapy company. The entity is primarily utilized as a vehicle for royalty-based financing and capital management to support the development and commercialization of ImmunityBio's pipeline. Its primary asset focus is Anktiva (N-803), an IL-15 superagonist complex approved for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. It plays a critical role in the parent company's strategic funding, notably through significant royalty interest agreements with investment firms like Oberland Capital. Through these arrangements, the company secures non-dilutive capital to advance its oncology and infectious disease programs. The entity operates as a key component of the broader NantWorks ecosystem founded by Dr. Patrick Soon-Shiong.